BioCentury | Nov 30, 2018
Company News

Management tracks: Inflazome, Clementia

...at Delenex Therapeutics AG and Auris Medical Holding AG (NASDAQ:EARS), respectively. Cell Medica Ltd. (London, U.K.) acquired Delenex...
BioCentury | Jul 25, 2016
Product Development

Collecting CAR parts

...the acquisition of antibody fragment company Delenex Therapeutics AG announced July 12. Cell Medica plans to use Delenex's...
...to control. Results were published in Blood in 2014. Human touch Cell Medica hopes that Delenex's...
...retroviral approach. The company plans to out-license Delenex's clinical and preclinical programs for further development. Delenex's...
BioCentury | Jul 18, 2016
Company News

Delenex, Cell Medica deal

...Cell Medica acquired Delenex. Cell Medica plans to use Delenex’s PENTRA antibody fragment platform to develop...
...fragment platform to develop next-generation chimeric antigen receptor (CAR)-modified cellular immunotherapies to treat solid tumors. Delenex’s...
...and integrated into Cell Medica’s global R&D operations. Cell Medica said it plans to out-license Delenex’s...
BioCentury | Jul 13, 2016
Company News

Cell Medica acquiring Delenex

...use Delenex's PENTRA antibody fragment platform to develop next-generation chimeric antigen receptor (CAR)-modified cellular immunotherapies. Delenex's...
BioCentury | Jul 13, 2015
Clinical News

Delenex preclinical data

...weeks significantly reduced tumor growth vs. an unrelated control single-chain antibody fragment (p<=0.004). Next year, Delenex...
...to start Phase I/II testing of the monovalent antibody fragment against VEGF-A to treat glioblastoma. Delenex Therapeutics AG...
BioCentury | Jul 13, 2015
Clinical News

Delenex preclinical data

...model of glioma, DLX1008 significantly improved survival and inhibited tumor growth vs. controls. Next year, Delenex...
...to start Phase I/II testing of the monovalent antibody fragment against VEGF-A to treat glioblastoma. Delenex Therapeutics AG...
BioCentury | May 4, 2015
Clinical News

DLX105 IV: Phase II data

...flare had almost completely disappeared within 1 week of injection. DLx10 5 was well tolerated. Delenex Therapeutics AG...
BioCentury | Oct 20, 2014
Emerging Company Profile

Rogne: Penetrating peptides

...is developing a topical formulation of a biologic for mild to moderate psoriasis. In September, Delenex Therapeutics AG...
...mRNA levels of pro-inflammatory molecules vs. placebo at day 14 in a Phase II trial. Delenex...
...out with systemic biologics, where "anti-IL-23s are better than anti-TNFs" on both safety and efficacy. Delenex...
BioCentury | Sep 15, 2014
Clinical News

DLX105 topical: Phase II data

...TNF alpha and T helper type 17 (Th17) cytokines vs. placebo. Based on the data, Delenex...
...its 2009 acquisition of ESBATech AG (see BioCentury, Sept. 21, 2009 & April 18, 2011). Delenex Therapeutics AG...
BioCentury | Sep 13, 2014
Clinical News

Delenex's DLX105 misses in psoriasis Phase II

...company said DLX105 significantly decreased mRNA levels of pro-inflammatory molecules vs. placebo at day 14. Delenex...
Items per page:
1 - 10 of 25
BioCentury | Nov 30, 2018
Company News

Management tracks: Inflazome, Clementia

...at Delenex Therapeutics AG and Auris Medical Holding AG (NASDAQ:EARS), respectively. Cell Medica Ltd. (London, U.K.) acquired Delenex...
BioCentury | Jul 25, 2016
Product Development

Collecting CAR parts

...the acquisition of antibody fragment company Delenex Therapeutics AG announced July 12. Cell Medica plans to use Delenex's...
...to control. Results were published in Blood in 2014. Human touch Cell Medica hopes that Delenex's...
...retroviral approach. The company plans to out-license Delenex's clinical and preclinical programs for further development. Delenex's...
BioCentury | Jul 18, 2016
Company News

Delenex, Cell Medica deal

...Cell Medica acquired Delenex. Cell Medica plans to use Delenex’s PENTRA antibody fragment platform to develop...
...fragment platform to develop next-generation chimeric antigen receptor (CAR)-modified cellular immunotherapies to treat solid tumors. Delenex’s...
...and integrated into Cell Medica’s global R&D operations. Cell Medica said it plans to out-license Delenex’s...
BioCentury | Jul 13, 2016
Company News

Cell Medica acquiring Delenex

...use Delenex's PENTRA antibody fragment platform to develop next-generation chimeric antigen receptor (CAR)-modified cellular immunotherapies. Delenex's...
BioCentury | Jul 13, 2015
Clinical News

Delenex preclinical data

...weeks significantly reduced tumor growth vs. an unrelated control single-chain antibody fragment (p<=0.004). Next year, Delenex...
...to start Phase I/II testing of the monovalent antibody fragment against VEGF-A to treat glioblastoma. Delenex Therapeutics AG...
BioCentury | Jul 13, 2015
Clinical News

Delenex preclinical data

...model of glioma, DLX1008 significantly improved survival and inhibited tumor growth vs. controls. Next year, Delenex...
...to start Phase I/II testing of the monovalent antibody fragment against VEGF-A to treat glioblastoma. Delenex Therapeutics AG...
BioCentury | May 4, 2015
Clinical News

DLX105 IV: Phase II data

...flare had almost completely disappeared within 1 week of injection. DLx10 5 was well tolerated. Delenex Therapeutics AG...
BioCentury | Oct 20, 2014
Emerging Company Profile

Rogne: Penetrating peptides

...is developing a topical formulation of a biologic for mild to moderate psoriasis. In September, Delenex Therapeutics AG...
...mRNA levels of pro-inflammatory molecules vs. placebo at day 14 in a Phase II trial. Delenex...
...out with systemic biologics, where "anti-IL-23s are better than anti-TNFs" on both safety and efficacy. Delenex...
BioCentury | Sep 15, 2014
Clinical News

DLX105 topical: Phase II data

...TNF alpha and T helper type 17 (Th17) cytokines vs. placebo. Based on the data, Delenex...
...its 2009 acquisition of ESBATech AG (see BioCentury, Sept. 21, 2009 & April 18, 2011). Delenex Therapeutics AG...
BioCentury | Sep 13, 2014
Clinical News

Delenex's DLX105 misses in psoriasis Phase II

...company said DLX105 significantly decreased mRNA levels of pro-inflammatory molecules vs. placebo at day 14. Delenex...
Items per page:
1 - 10 of 25